Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

41 results about "Interleukin-4 receptor" patented technology

The interleukin 4 receptor is a type I cytokine receptor. IL4R is its human gene.

Storage stable powder compositions of interleukin-4 receptor

The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
Owner:NOVARTIS FARMA

Antagonists of interleukin-2 receptor

Novel human interleukin-2 (IL-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed. In addition, the invention provides recombinant expression vectors comprising the nucleic acid molecules of this invention and host cells into which expression vectors have been introduced. Pharmaceutical compositions are included comprising a therapeutically effective amount of a human IL-2 mutein of the invention and a pharmaceutically acceptable carrier. The IL-2 muteins can be used in pharmaceutical compositions for use in treatment of cancer and in stimulating the immune response.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Anti-human interleukin-4 receptor alpha monoclonal antibody, preparation method and applications thereof

The present invention belongs to the field of antibodies, and more particularly discloses a recombinant anti-human hIL-4R[alpha] monoclonal antibody, a preparation method and applications thereof. According to the present invention, the anti-human hIL-4R[alpha] monoclonal antibody can specifically bind to human hIL-4R[alpha], can well inhibit hIL-4 and hIL-13 induced proliferation of various celllines and the like, and can be used for preparing drugs for treatment of immune mediated Inflammatory reaction diseases.
Owner:SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD

Antibodies to interleukin-4 receptors and uses thereof

InactiveUS20050118176A1Preventing allograft rejectionGood immunosuppressive activityPeptide/protein ingredientsMicroorganism based processesIl 4 receptorMammal
Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
Owner:IMMUNEX CORP

Methods for Treating Severe Atopic Dermatitis by Administering an IL-4R Inhibitor

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
Owner:SANOFI BIOTECH SAS +1

Methods for treating skin infection by administering an IL-4R antagonist

The present invention provides methods for treating, preventing or ameliorating skin infections, including bacterial and viral infections. In certain embodiments, the invention provides methods to reduce skin infection in a patient with atopic dermatitis (AD). Also provided are methods for improving skin barrier function, and methods for reducing the risk of inflammation due to microbial infection in a patient in need thereof. The methods of the present invention comprise administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1

Methods for preventing or treating allergy by administering an il-4r antagonist

ActiveUS20190183973A1Treat and reduce and prevent allergy and allergen sensitizationPeptide/protein ingredientsPharmaceutical delivery mechanismDiseaseAtopic dermatitis
The present invention provides methods for preventing or treating allergy. Also provided are methods for reducing the susceptibility to an allergen in a subject in need thereof. In certain embodiments, the subject has a disease or disorder selected from the group consisting of atopic dermatitis, asthma, allergic rhinitis, and eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1

Methods for treating or preventing asthma by administering an il-4r antagonist

The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1

Methods for treating or preventing asthma by administering an il-4r antagonist

The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC +1

Methods for treating atopic dermatitis by administering an il-4r inhibitor

The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.
Owner:REGENERON PHARM INC

Urine protein marker for chronic pancreatitis and application thereof

The present application relates to urinary protein markers for chronic pancreatitis and uses thereof. Specifically, this application relates to the use of urine protein markers obtained by using chronic pancreatitis disease models and mass spectrometry analysis in the early diagnosis of human chronic pancreatitis disease and the use of disease course monitoring. The urine protein markers are selected from Igγ‑1 chain C domain, nucleonectin‑2, beta‑2‑microglobulin, interleukin‑4 receptor alpha subunit, phosphoglycerate mutase 1, dipeptidyl peptidase 2, secreted pyrophosphoprotein 24, glycans Core protein, endothelial cell selective adhesion molecule, nestin-2, serum amyloid substance p, nerve cell adhesion molecule 1, etc. In this application, the obtained differential protein in urine provides a non-invasive and convenient option for early diagnosis and subsequent treatment of chronic pancreatitis.
Owner:BEIJING NORMAL UNIVERSITY

Chimeric Antigen Receptors

Disclosed herein are chimeric antigen receptors (CARs) comprising an intracellular segment comprising an interleukin receptor chain, a JAK-binding motif, a Signal Transducer and Activator of Transcription (STAT) 5 association motif and / or a CD3ζ intracellular signaling domain comprising an exogenous STAT3 association motif, as well as cells and 5 compositions comprising said CARs and uses thereof.
Owner:UNIV HEALTH NETWORK +1

sil-4r-nap (soluble interleukin-4 receptor-neutrophil-activating protein) fusion gene

The invention relates to the field of genes, and provides a fusion gene which is used for resisting asthma. The gene comprises a fragment (a) coding a soluble interleukin-4 receptor (sIR-4R) and a fragment (b) coding a helicobacter pylori neutrophil-activating protein (HP-NAP). The gene can be connected to a vector to achieve a good effect on resisting asthma.
Owner:ZHENGZHOU UNIV

IL-4R antagonist and microorganism for generating the IL-4R antagonist

The invention relates to a new interleukin-4 receptor (IL-4R) antagonist (shown in formula I) and a pharmaceutical composition containing the antagonist. The invention also relates to an application of the IL-4R antagonist in preparing medicines for treating asthma or tumor. The invention further relates to microorganism for generating the new IL-4R antagonist (shown in formula I) and a method for preparing the new IL-4R antagonist by using the microorganism.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Method for detecting in-vitro activity of recombined human interleukin-12 by using cell with interleukin-12 receptor and application

The invention discloses a method for detecting the in-vitro activity of recombined human interleukin-12 by using a cell with an interleukin-12 receptor and application. The method comprises the following steps of (1) taking out the frozen cell with the interleukin-12 receptor from a liquid nitrogen tank, and performing recovery activation cultivation till the logarithm growth period is reached; (2) inducing the cell with the interleukin-12 receptor through a recombined human interleukin-12 standard substance under different concentrations to generate gamma interferon to obtain the concentration value ED50s of the recombined human interleukin-12 standard substances; (3) inducing the cell with the interleukin-12 receptor through a recombined human interleukin-12 protein to be detected under different concentrations to generate the gamma interferon to obtain a concentration value ED50r of the recombined human interleukin-12 protein to be detected; and (4) obtaining the in-vitro activity Pr of the recombined human interleukin-12 protein to be detected according to a formula Pr=Ps*ED50s / ED50r.
Owner:QINGDAO KANGLITAI PHARMA

Pharmaceutical composition for treating or preventing obstructive sleep apnea

InactiveCN108339118AImprove night sleep snoringImprove apnea frequencyVertebrate antigen ingredientsAntibody ingredientsAntigenAntigen Binding Fragment
The invention discloses an antagonist or antibody of an interleukin-4 receptor (IL-4R) and an antigen-binding fragment thereof and / or a use of an antagonist or antibody of an interleukin-6 (IL-6) andan antigen-binding fragment thereof in preparation of a pharmaceutical composition for treating or preventing obstructive sleep apnea. The invention also discloses a pharmaceutical composition for treating or preventing obstructive sleep apnea. The active ingredients of the drug comprise an antagonist of an interleukin-4 receptor (IL-4R) or its antibody and antigen-binding fragment, or an antagonist or antibody of an interleukin-6 (IL-6) and an antigen-binding fragment thereof.
Owner:REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products